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Original Article

Protection Effect of Exogenous Fibroblast Growth Factor 21
on the Kidney Injury in Vascular Calcification Rats
Yu‑Chen Shi1, Wei‑Wei Lu2,3, Yue‑Long Hou4, Kun Fu5, Feng Gan1,5, Shu-Juan Cheng1, Shao-Ping Wang1, Yong-Fen Qi4, Jing‑Hua Liu1
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, China
2
Department of Physiology, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China
3
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky, USA
4
Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Peking University Health Science Center, Beijing 100191, China
5
Department of Cardiology, Beijing Aerospace General Hospital, Beijing 100076, China

1

Abstract
Background: Chronic kidney disease (CKD) is closely related to the cardiovascular events in vascular calcification (VC). However, little
has known about the characteristics of kidney injury caused by VC. Fibroblast growth factor 21 (FGF21) is an endocrine factor, which takes
part in various metabolic actions with the potential to alleviate metabolic disorder diseases. Even FGF21 has been regarded as a biomarker
in CKD, the role of FGF21 in CKD remains unclear. Therefore, in this study, we evaluate the FGF21 on the kidney injury in VC rats.
Methods: The male Sprague‑Dawley rats were divided into three groups: (1) control group, (2) Vitamin D3 plus nicotine (VDN)‑induced
VC group, (3) FGF21‑treated VDN group. After 4 weeks, the rats were killed and the blood was collected for serum creatinine, urea
nitrogen, calcium, and phosphate measurement. Moreover, the renal tissues were homogenized for alkaline phosphatases (ALPs) activity
and calcium content. The levels of FGF21 protein were measured by radioimmunoassay. The levels of β‑Klotho and FGF receptor
1 (FGFR1) protein were measured by enzyme‑linked immunosorbent assay (ELISA). The structural damage and calcifications in aortas
were stained by Alizarin‑red S. Moreover, the structure of kidney was observed by hematoxylin and eosin staining.
Results: The renal function impairment caused by VDN modeling was ameliorated by FGF21 treatment, inhibited the elevated serum
creatinine and urea level by 20.5% (34.750 ± 4.334 μmol/L vs. 27.630 ± 2.387 μmol/L) and 4.0% (7.038 ± 0.590 mmol/L vs. 6.763 ± 0.374
mmol/L; P < 0.01), respectively, together with the structural damages of glomerular atrophy and renal interstitial fibrosis. FGF21 treatment
downregulated the ALP activity, calcium content in the kidney of VC rats by 42.1% (P < 0.01) and 11.7% (P < 0.05) as well as ameliorated
the aortic injury and calcification as compared with VDN treatment alone group, indicating an ameliorative effect on VC. ELISA assays
showed that the expression of β‑Klotho, a component of FGF21 receptor system, was increased in VDN‑treated VC rats by 37.4% (6.588 ±
0.957 pg/mg vs. 9.054 ± 0.963 pg/mg; P < 0.01), indicating an FGF21‑resistant state. Moreover, FGF21 treatment downregulated the level
of β‑Klotho in renal tissue by 16.7% (9.054 ± 0.963 pg/mg vs. 7.544 ± 1.362 pg/mg; P < 0.05). However, the level of FGFR1, the receptor
of FGF21, kept unchanged under VDN and VDN plus FGF21 administration (0.191 ± 0.0376 ng/mg vs. 0.189 ± 0.032 ng/mg vs. 0.181 ±
0.034 ng/mg; P > 0.05).
Conclusions: In the present study, FGF21 was observed to ameliorate the kidney injury in VDN‑induced VC rats. FGF21 might be a
potential therapeutic factor in CKD by cutting off the vicious circle between VC and kidney injury.
Key words: Chronic; Fibroblast Growth Factor 21; Renal Insufficiency; Vascular Calcification; β‑Klotho

Introduction
Chronic kidney disease (CKD) is a disease characterized
by chronic renal structural and functional progressive
injury.[1] As the end stage of various kidney diseases, CKD
has a wide range of pathogenic factors such as hypertension,
diabetes, atherosclerosis, metabolic disorders,[2] and virus
infection.[3] Among these risk factors of CKD, vascular
calcification (VC) is one of the important factors.[4,5] Recent
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studies have shown that renal artery calcification is a vital
risk factor for CKD and microalbuminuria.[6] Moreover,
the correlation between renal artery calcification and
renal artery atheromatosis, an important inducement of
CKD, has also been confirmed.[7] With the characteristic of
calcium and phosphorus depositing in vessel walls, VC is
motivated by a phenotypic modulation from vascular cell to
osteoblast‑like cell, which can be observed in many diseases
including diabetes, atherosclerosis, and CKD.[8] In patients
with CKD, clinical studies have found the morbidity of VC
is much higher than healthy people, which results from the
disorder of calcium and phosphorus metabolism caused by
renal function impairment.[9‑11] Meanwhile, hypertension
and intraglomerular high pressure due to VC, together
with micro‑VC in kidney, may accelerate the progress of
CKD.[12,13] As VC and CKD are in reciprocal causation,[14]
inhibiting the calcification in kidney may be an important
aspect to control CKD.
Differing from the traditional view of points that VC is a
passive process, the latest study showed that the process of
VC was similar to the process of skeleton formation.[6] In fact,
VC is an active, preventable, and reversible process regulated
by various cytokines.[6,15‑17] The pathological mechanism
of VC mainly related to the increase of intracellular
alkaline phosphatase (ALP) activity, the high expression of
bone‑related proteins, and the transform of vascular smooth
muscle cell phenotype.[10,18] Therefore, inhibition of the
particular link in the process of VC may be beneficial for
reversing the development of calcification‑related diseases.
Although little research on the kidney injury resulted from
VC was reported, there are still evidences which indicate
that, in the animal model induced by Vitamin D3 plus
nicotine (VDN), not only was there large and middle arterial
VC but also the calcium overload and micro‑VC could
be observed in kidney.[19] Thus, VC may be an important
stimulus in the process of CKD.
Fibroblast growth factor 21 (FGF21) is a member of the
FGF superfamily, which is predominantly generated in liver,
then secreted into circulation, and could affect throughout
the body.[20,21] By forming a trimer with the receptor FGF
receptor 1 (FGFR1) and its cofactor β‑Klotho,[22] FGF21
can activate downstream signaling pathways to exert an
antagonistic effect on the apoptosis of vascular endothelial
cells,[23] inhibiting atherosclerosis[24] and the calcification
of vascular smooth muscle cells.[25] In CKD patients, the
increased serum FGF21 level is regarded as a potential
biomarker for kidney injury.[26] As renal excretion is regarded
as a major route to eliminate FGF21 from circulation,[27] it
is reasonable to hypothesize that FGF21 may involve in the
regulation of the process of CKD.
Whether VC could cause kidney injury is unknown, and the
function of high expression of FGF21 in CKD is still unclear.
In this study, we evaluated the changes of the structure and
function of kidney in VDN‑treated VC rats. In addition,
the level of endogenous FGF21, β‑Klotho, and its receptor
FGFR1 in VDN‑induced VC rats was determined. Then,
Chinese Medical Journal ¦ March 5, 2018 ¦ Volume 131 ¦ Issue 5

exogenous FGF21 was administrated to clarify whether
FGF21 inhibits the process of kidney injury in VC rats.

Methods
Ethical approval

The study was approved by the Institutional Animal Care
and Use Committee of the Capital Medical University.
The experimental procedures and protocols performed in
this study were in concordance with ethical approval for
Animals' Model Research Committee of the Capital Medical
University.

Materials and reagents

FGF21 was from Phoenix Pharmaceuticals (Belmont, CA,
USA). Enzyme‑linked immunosorbent assay (ELISA) kit
for β‑Klotho and FGFR1 was purchased from Cloud‑Clone
Co. (Wuhan, Hubei, China). The ALP kit was from Jiancheng
Biological Co. (Nanjing, Jiangsu, China). The calcium
assay kit was from Zhongsheng Biosino Bio‑technology
and Science INC (Beijing, China). The VDN was bought
from Sigma‑Aldrich (St. Louis, MO, USA). The urea
determination kit and creatinine determination kit were
purchased from Zhongsheng Biosino Bio‑technology and
Science INC (Beijing, China). The regents for calcium
and phosphate determination were from North Beijing
Xinchuangyuan seized Biological Technology Co.
Ltd. (Beijing, China). Alzet Mini‑Osmotic Pumps, model
2004, were from Durect Corp. (Cupertino, CA, USA). All
other reagents were of analytical grade.

Animal and treatments

Eight‑week‑aged male Sprague‑Dawley rats were
purchased from the Laboratory Animal Center of Peking
University (Beijing, China) and housed in standard
laboratory temperature and humidity conditions with a
12 h light/dark cycle. The rats were divided into three
groups randomly (n = 8): control group (NC group),
model group (VDN group), and FGF21 treatment
group (VDN + FGF21 group). The preparation for
the VC model was made as previously described. [28]
Briefly, rats were intragastric administrated with nicotine
(25 mg/kg in 5 ml peanut oil) plus injected with Vitamin
D3 intramuscularly (3 × 105 U/kg) at 9 a.m. on day 1. The
nicotine administration was repeated at 5 p.m. The modeling
continued for 4 weeks. For FGF21 treatment, the rats were
anesthetized by pentobarbital, and then an osmotic minipump
was implanted subcutaneously. The VDN and VDN + FGF21
group were infused with vehicle or FGF21 (70 µg·kg−1·d−1),
respectively, by osmotic minipump for 4 weeks.[23] Rats in
the control group received the injection of saline and oral
gavage of peanut oil, together with the infusion of saline
with minipump.

Measurement of fibroblast growth factor 21 level in
renal tissue

Briefly, the renal tissue (100 mg) was excised and
immediately acidified with 1.0 mol/L acetic acid and then
heated at 100°C for 10 min to inactivate proteases. Then,
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the tissue was homogenized and centrifuged at 17,000 g
for 20 min. Radioimmunoassay (RIA) was performed to
measure tissue FGF21 content in supernatants by use of a
commercial RIA kit (Phoenix Pharmaceuticals) according
to the manufacturer’s instructions.

One unit was defined as 1 g tissue protein producing 1 mg
phenol for 15 min.[30]

Measurement of serum urea nitrogen and creatinine

Briefly, 10 mg of nephridial tissue was homogenized at 4°C in
PBS, and then the mixture was further treated by ultrasonication.
After centrifugation at 5000 g for 5 min at 4°C, the protein
content in supernatant was determined by the Bradford method.
The level of FGFR1 and β‑Klotho in supernatants was measure
by ELISA kit according to the manufacturer’s instructions.

Before execution, the rats were anesthetized and the blood
was collected by intracardiac puncture. The urea level in
serum was measured by a urea determination kit using
glutamate dehydrogenase method. Likewise, the serum
creatinine level was measured by a creatinine determination
kit according to the manufacturer’s instructions.

Measurement of serum calcium and phosphate

The levels of serum calcium and phosphate were
measured by automatic biochemical analyzer (TOSHIBA
TBA‑40FR, Japan) with supplementary reagents,
respectively.

Hematoxylin and eosin staining for nephritic tissue

The nephritic tissue was fixed in 4% paraformaldehyde
overnight, then embedded in paraffin, and sectioned for
hematoxylin and eosin (H and E) staining. Briefly, the
sections were stained by hematoxylin; after washing and
treating with 1% acidic alcohol, the sections were stained
by eosin. Then, the sections were washed, dehydrated, and
treated by xylene before microscopy. The cross sections
were evaluated by Olympus BX 50 microscope (Olympus
Optical Tokyo, Japan).

Alizarin red staining for aortic tissues

For Alizarin‑red S staining, aortic slides were dehydrated,
rinsed rapidly in distilled water, and placed in an Alizarin‑red
S (Sigma, St. Louis, MO, USA) staining solution at room
temperature for 30 min. When a red‑orange color appeared,
any unbound stain was removed from the tissues, and then
the tissues were photographed under an Olympus BX 50
microscope.

Measurement of calcium content in kidney

The renal tissue was first dried at 55°C and weighed, then
dissolved in HNO3, dried at 180°C, and re‑dissolved with
a blank solution (27 nmol/L KCl and 27 μmol/L LaCl3).
Calcium levels were determined by colorimetry through a
reaction with o‑cresolphthalein complexon and normalized
to renal tissues dry weight.[29]

Measurement of alkaline phosphatase activity in kidney

The renal tissues were homogenized in ice‑cold buffer
(20 mmol/L HEPES, 0.2% NP‑40, and 20 mmol/L MgCl2,
pH 7.4). After centrifugation at 8000 g for 10 min at 4°C,
the protein content in supernatant was determined by the
Bradford method. ALP activity was measured using the
ALP activity assay kit according to the manufacturer’s
instructions. Briefly, the 1 ml of supernatant was mixed with
the reaction buffer and then incubated at 37°C for 15 min.
After incubation, 1.5 ml of developer was added, and then
the absorbance at 520 nm was recorded. The activity of
ALP in each well was calculated from the standard curve.
534

Enzyme‑linked immunosorbent assay for fibroblast
growth factor receptor 1 and β‑Klotho in nephridial
tissue

Statistical analysis

All calculations were performed using GraphPad Prism
version 5.0 statistical software (GraphPad Software,
San Diego, CA, USA). The data were calculated as
the mean ± standard deviation (SD) from at least three
independent experiments and analyzed by a one‑way
ANOVA. The Student’s t‑test was used when only two
groups were compared. Difference was accepted at P < 0.05.
A value of P < 0.05 was considered statistically significant,
and a P < 0.01 was considered very statistically significant.

Results
Increased expression of fibroblast growth factor 21 in
kidney tissue

First, we used RIA to detect the endogenous FGF21 in
VDN‑induced VC rats. Results showed that the FGF21
expression in kidney tissue of VDN group increased
significantly compared to the control group by 2.44‑fold (0.248
± 0.108 vs. 0.607 ± 0.317 ng/mg, P < 0.05), indicating that
FGF21 may be involved in the regulation of kidney injury
results from VC.

Fibroblast growth factor 21 ameliorated the renal
function impairment in vascular calcification rats

To evaluate the protective effect of exogenous FGF21
on renal function, the serum creatinine and urea were
tested [Figure 1a and 1b]. The level of serum creatinine and
urea increased dramatically in VDN group compared to the
control group by 34.3% and 29.1% (P < 0.01), respectively,
indicating that the renal function was damaged. Meanwhile,
treatment with FGF21 inhibited the elevated serum creatinine
and urea level by 20.5% and 4.0% (P < 0.01), respectively.
Likewise, H and E staining showed a normal renal glomerulus
structure in the control group. In contrast, VDN‑treated rats
exhibited pathological changes characterized by glomerular
atrophy (white arrow) and prominent renal interstitial
fibrosis (yellow arrows) [Figure 1c]. The rats treated with
FGF21 showed less structural lesions than VDN group.
These results revealed that FGF21 could protect the renal
injury in VC rats.

Fibroblast growth factor 21 attenuated calcification in
the kidney of Vitamin D3 plus nicotine‑treated rats

We further investigated whether FGF21 decreased the
calcification rate of kidney. Compared with the control group,
Chinese Medical Journal ¦ March 5, 2018 ¦ Volume 131 ¦ Issue 5
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b

c

Figure 1: Effect of exogenous FGF21 on the blood creatinine level in VDN‑induced VC rats (n = 8; a); effect of exogenous FGF21 on the urea level
in VDN‑induced VC rats (n = 8; b); effect of exogenous FGF21 on the histopathology of kidney in VDN‑induced VC rats (original magnification
×200). The histological sections of kidney were stained by H and E. The pathologic changes of glomerulus atrophy were marked by white arrows
and prominent renal interstitial fibrosis were marked by yellow arrows (c). *P < 0.01 compared with the normal control group. †P < 0.01 compared
with the VDN group. FGF21: Fibroblast growth factor 21; VC: Vascular calcification; VDN: Vitamin D3 plus nicotine.

the calcium content was 36.1% (P < 0.01) higher in VC rats.
FGF21 treatment significantly decreased the calcium level
in renal tissue by 29.1% (P < 0.05) as compared with VDN
treatment alone group [Figure 2a]. Besides VC rats showed
increased ALP activity in kidney by 2.63‑fold (P < 0.01).
FGF21 downregulated the VDN‑increased ALP activity in the
renal tissue of rats by 42.1% (P < 0.01) [Figure 2b]. In addition,
Alizarin‑red S staining showed thickened vessel walls,
disordered elastic fibers, and widespread calcifications in aortas
of VDN group [Figure 2e]. Decreased calcium‑phosphate salt
deposition in FGF21‑treated VC aortas was further confirmed
compared with the VDN rats [Figure 2e]. However, the serum
calcium and phosphate level did not response neither to VDN
nor to FGF21 treatment (P > 0.05) [Figure 2c and 2d].

Fibroblast growth factor 21 inhibited the expression of
β‑Klotho in calcification kidney

FGF21 can only function by forming trimerization with
FGFR1 and β‑Klotho, so the effect of VDN modeling
and FGF21 treatment on the level of renal FGFR1 and
β‑Klotho was further investigated. In accordance with
endogenous FGF21 [Figure 3a], the β‑Klotho level in kidney
increased significantly in VC rats by 37.4% (P < 0.01).
FGF21 administration significantly suppressed the
increase of β‑Klotho level compared to the VDN group by
16.7% (P < 0.05). However, no change was observed in the
level of renal FGFR1 in neither VDN nor VDN + FGF21
treatment (P > 0.05) [Figure 3b]. These results indicated that
not FGFR1 but β‑Klotho was involved in the regulation of
kidney injury in VC model by FGF21.

Discussion
Administration of VDN to rat is a widely used modeling
method to cause VC, in which calcium overload generally
Chinese Medical Journal ¦ March 5, 2018 ¦ Volume 131 ¦ Issue 5

occurred in many tissues and organs including aorta,
heart, and kidney.[28,31,32] In our research, structural and
functional injuries in kidney were observed in VDN‑treated
rat [Figure 1a–1c]. In addition, the VC biomarkers were
also measured in renal tissue. ALP, an important marker
for the early differentiation of osteoblast, plays a central
role in ossification process.[33,34] Being similar with the
calcium content, the increased level of ALP activity and
calcium content in the renal tissue indicate that calcification
is in progress in the kidney [Figure 2a and 2b]. However,
no substantial change was observed in the blood calcium
and phosphorus between model group and the control
group, which indicated that the calcification in kidney
was independent from blood calcium and phosphorus
[Figure 2c and 2d]. Since the increase of serum calcium
and phosphate level could be observed only in 4–5 Stage
CKD, these results also demonstrated that, in VDN‑treated
VC model, the kidney injury happened at early phase.[35]
At present, the change of serum FGF21 in CKD patients
has already been observed, but the function of FGF21 in
the process of renal damage was still unclear. In our study,
an increased expression of endogenous FGF21 in kidney
was observed in VDN rats, suggesting that FGF21 may be
involved in the regulation of kidney injury and calcification.
Therefore, exogenous FGF21 was administrated to VDN
modeling rats. As shown in Figure 2a–2c, exogenous
FGF21 can downregulate the serum creatinine and blood
urea levels of the VC rats and reverse the kidney structural
damage, which means FGF21 can alleviate the injury of
the renal structure and function in VC rats. At the same
time, the renal ALP activity and calcium content were also
suppressed by FGF21 [Figure 2a and 2b]. These results
demonstrated that FGF21 could protect the kidney from
injury and calcification in situ. Meanwhile, the protective
535
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Figure 2: Effect of exogenous FGF21 on the renal calcium level in VDN‑induced VC rats (n = 6–8; a); effect of exogenous FGF21 on renal activity in
VDN‑induced VC rats (n = 6–8; b); effect of exogenous FGF21 on serum level of calcium in VDN‑induced VC rats (n = 8; c); effect of exogenous
FGF21 on serum level of phosphate in VDN‑induced VC rats (n = 8; d); effect of exogenous FGF21 in aortas of VDN‑induced VC rats by Alizarin‑red
S staining (original magnification ×200; d). *P < 0.01 compared with the normal control group. †P < 0.05 compared with the VDN group. ‡P < 0.01
compared with the VDN group. FGF21: Fibroblast growth factor 21; VC: Vascular calcification; VDN: Vitamin D3 plus nicotine; ALP: Alkaline phosphatase.

a

b

Figure 3: Effect of exogenous FGF21 on the levels of renal β‑Klotho in the kidney of VDN‑induced VC rats (n = 8) by ELISA (a). Effect of
exogenous FGF21 on the levels of renal FGFR1 in VDN‑induced VC rats (n = 8) by ELISA (b). *P < 0.01 compared with the normal control
group. †P < 0.05 compared with the VDN group. FGF21: Fibroblast growth factor 21; VC: Vascular calcification; VDN: Vitamin D3 plus nicotine;
ELISA: Enzyme‑linked immunosorbent assay.

effect of FGF21 was independent of regulating serum
calcium and phosphate.
As well known, FGF21‑FGFR1‑β‑Klotho tripolymer is
essential for FGF21 to function.[22] In our study, different
from the level of FGFR1, which kept unchanged under
VDN and VDN + FGF21 administration, the level of renal
536

β‑Klotho increased significantly in the model group, in
accordance with the endogenous renal FGF21 [Figure 3a].
The high expression of renal FGF21 and β‑Klotho suggested
a high activity of FGF21 signaling pathway in kidney, which
is an FGF21‑resistant state under VDN administration. While
exogenous FGF21 treatment can overcome this resistant state
Chinese Medical Journal ¦ March 5, 2018 ¦ Volume 131 ¦ Issue 5
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and protect the kidney from injury. The similar result was
also reported by Kim et al.[36] in the kidney of db/db mice,
which may be partly due to db/db mice and VDN‑treated
rats all belonging to the metabolic disorders model. These
results indicate that β‑Klotho plays an important role in the
activation of FGF21 signaling, which may be a key target for
the treatment of the diseases with the feature of metabolic
disorders. In fact, in our study, it is by activating FGF21
signaling pathway that exogenous FGF21 ameliorates the
FGF21 resistance and then impair the kidney injury in VDN
rats.

9.

In summary, kidney injury and calcification in situ were
observed in VDN‑induced VC rats. At the same time, the
increased level of endogenous FGF21 and β‑Klotho in
kidney indicates a negative feedback regulation. Exogenous
FGF21 treatment can ameliorate the kidney injury and
calcification, indicating that FGF21 might be a potential
therapeutic target in CKD by cutting off the vicious circle
between VC and kidney injury.
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外源性纤维细胞生长因子21对血管钙化大鼠肾脏损伤的
保护作用
摘要
背景： 在血管钙化中，慢性肾脏病与心血管事件发生密切相关。然而，血管钙化对肾脏损伤的作用知之甚少。FGF21是一种
内分泌因子，其在多种代谢过程中发挥作用，并有治疗代谢紊乱性疾病的潜能。尽管FGF21已经被视为一种慢性肾脏病的生物
标志物，但其在慢性肾脏病中的作用尚不明确。因此，本实验旨在观察血管钙化对大鼠肾脏结构及功能的损伤情况，以及与肾
脏组织局部成纤维细胞生长因子21（Fibroblast growth factor 21，FGF21）、β-Klotho及成纤维细胞生长因子受体1（Fibroblast
growth factor receptor 1，FGFR1）表达变化关系；同时探讨外源性给予FGF21对血管钙化大鼠肾脏损伤的影响及可能的机制。
方法： 雄性SD大鼠按电脑随机数字表法分为正常组（Con）、钙化组（VDN）及钙化+FGF21组（FGF21），每组8只。钙化
组采用维生素D3联合尼古丁诱导大鼠血管钙化模型。钙化+FGF21组在钙化组基础上，予大鼠皮下埋入含有FGF21溶液的渗透
泵，微量渗透泵持续给药，剂量为70 ug/kg/d。其余两组大鼠皮下埋入含有等量生理盐水的渗透泵。4周后取动物肾脏组织行碱
性磷酸酶及钙含量检测。以肌氨酸氧化酶法检测大鼠血清肌酐浓度，以紫外-谷氨酸脱氢酶法检测大鼠血清尿素氮浓度，以生化
法检测大鼠血钙及血磷浓度，以放射免疫法检测大鼠肾脏组织FGF21蛋白含量，以酶联免疫吸附法检测大鼠肾脏组织β-Klotho
及FGFR1蛋白含量，以苏木素伊红染色观察肾脏组织结构，以茜素红染色法观察主动脉结构及钙化程度。
结果：FGF21可改善维生素D加尼古丁诱导的血管钙化导致的肾脏损伤。与单纯血管钙化组相比，其可分别降低20.5%及4%
(p < 0.01)的血肌酐和尿素氮。并可减轻肾小球及肾间质的结构损伤。同时相比于单纯血管钙化组，FGF21可分别降低ALP及
钙含量42.1% (p < 0.01)及11.7% (p < 0.05)，并能减少主动脉损伤及钙化程度。这些结果表明，FGF21可以减轻血管钙化导致
的肾损伤。另外，作为FGF21三聚体的组成部分，ELISA结果显示，β-Klotho在血管钙化大鼠中升高了37.4% (p < 0.01),预示
机体处于FGF21抵抗状态。而外源性给予FGF21后，大鼠肾脏组织β-Klotho下调16.7% (p < 0.05)。但是FGF21的受体FGFR1在
三种大鼠中无显著性差异 (p > 0.05)。
结论：大剂量维生素D3肌肉注射联合尼古丁灌胃可导致大鼠肾脏组织局部钙超载及微血管钙化形成，并导致肾功能不全，出
现早期CKD临床表现。同时病变肾脏组织局部FGF21和β-Klotho表达量上调，而FGFR1在肾脏组织局部未见明显变化。外源性
给予FGF21可改善血管钙化情况及肾脏结构与功能，同时下调β-Klotho表达量。FGF21可能通过切断血管钙化与肾脏损伤之间
的恶性循环成为治疗血管钙化导致的肾损伤的治疗因子。

